153 related articles for article (PubMed ID: 7839427)
1. Liposomal amphotericin B prevents invasive fungal infections in liver transplant recipients. A randomized, placebo-controlled study.
Tollemar J; Höckerstedt K; Ericzon BG; Jalanko H; Ringdén O
Transplantation; 1995 Jan; 59(1):45-50. PubMed ID: 7839427
[TBL] [Abstract][Full Text] [Related]
2. Randomized double-blind study of liposomal amphotericin B (Ambisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients.
Tollemar J; Ringdén O; Andersson S; Sundberg B; Ljungman P; Tydén G
Bone Marrow Transplant; 1993 Dec; 12(6):577-82. PubMed ID: 8136741
[TBL] [Abstract][Full Text] [Related]
3. Liposomal amphotericin B (AmBisome) for fungal infections in immunocompromised adults and children.
Tollemar J; Klingspor L; Ringdén O
Clin Microbiol Infect; 2001; 7 Suppl 2():68-79. PubMed ID: 11525221
[TBL] [Abstract][Full Text] [Related]
4. Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: a randomised, double-blind, placebo-controlled study.
Kelsey SM; Goldman JM; McCann S; Newland AC; Scarffe JH; Oppenheim BA; Mufti GJ
Bone Marrow Transplant; 1999 Jan; 23(2):163-8. PubMed ID: 10197802
[TBL] [Abstract][Full Text] [Related]
5. A retrospective clinical comparison between antifungal treatment with liposomal amphotericin B (AmBisome) and conventional amphotericin B in transplant recipients.
Tollemar J; Andersson S; Ringdén O; Tydén G
Mycoses; 1992; 35(9-10):215-20. PubMed ID: 1291871
[TBL] [Abstract][Full Text] [Related]
6. Systemic mycoses during prophylactical use of liposomal amphotericin B (Ambisome) after liver transplantation.
Lorf T; Braun F; Rüchel R; Müller A; Sattler B; Ringe B
Mycoses; 1999 Apr; 42(1-2):47-53. PubMed ID: 10394848
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients.
Ringdén O; Meunier F; Tollemar J; Ricci P; Tura S; Kuse E; Viviani MA; Gorin NC; Klastersky J; Fenaux P
J Antimicrob Chemother; 1991 Oct; 28 Suppl B():73-82. PubMed ID: 1778894
[TBL] [Abstract][Full Text] [Related]
8. Prophylaxis with liposomal amphotericin B (AmBisome) prevents fungal infections in liver transplant recipients: long-term results of a randomized, placebo-controlled trial.
Tollemar J; Höckerstedt K; Ericzon BG; Jalanko H; Ringdén O
Transplant Proc; 1995 Feb; 27(1):1195-8. PubMed ID: 7878847
[No Abstract] [Full Text] [Related]
9. Surveillance and treatment of liver transplant recipients for candidiasis and aspergillosis.
Viviani MA; Tortorano AM; Malaspina C; Colledan M; Paone G; Rossi G; Bordone G; Pagano A
Eur J Epidemiol; 1992 May; 8(3):433-6. PubMed ID: 1397207
[TBL] [Abstract][Full Text] [Related]
10. Liposomal amphotericin B (AmBisome): efficacy and safety of low-dose therapy in pulmonary fungal infections.
Lequaglie C
J Antimicrob Chemother; 2002 Feb; 49 Suppl 1():49-50. PubMed ID: 11801581
[TBL] [Abstract][Full Text] [Related]
11. Liposomal amphotericin B (AmBisome) treatment of invasive fungal infections in immunocompromised children.
Ringdén O; Tollemar J
Mycoses; 1993; 36(5-6):187-92. PubMed ID: 8264715
[TBL] [Abstract][Full Text] [Related]
12. Liposomal amphotericin B in the treatment of fungal infections in neutropenic patients: a single-centre experience of 133 episodes in 116 patients.
Mills W; Chopra R; Linch DC; Goldstone AH
Br J Haematol; 1994 Apr; 86(4):754-60. PubMed ID: 7918068
[TBL] [Abstract][Full Text] [Related]
13. Low-dose amphotericin for prevention of serious fungal infection following liver transplantation.
Shah T; Lai WK; Gow P; Leeming J; Mutimer D
Transpl Infect Dis; 2005; 7(3-4):126-32. PubMed ID: 16390401
[TBL] [Abstract][Full Text] [Related]
14. Liposomal amphotericin B. Therapeutic use in the management of fungal infections and visceral leishmaniasis.
Coukell AJ; Brogden RN
Drugs; 1998 Apr; 55(4):585-612. PubMed ID: 9561346
[TBL] [Abstract][Full Text] [Related]
15. Liposomal amphotericin B (AmBisome) therapy in invasive fungal infections. Evaluation of United Kingdom compassionate use data.
Ng TT; Denning DW
Arch Intern Med; 1995 May; 155(10):1093-8. PubMed ID: 7748054
[TBL] [Abstract][Full Text] [Related]
16. Prevention of invasive fungal infections in liver transplant recipients: the role of prophylaxis with lipid formulations of amphotericin B in high-risk patients.
Fortún J; Martín-Davila P; Moreno S; Barcena R; de Vicente E; Honrubia A; García M; Nuño J; Candela A; Uriarte M; Pintado V
J Antimicrob Chemother; 2003 Nov; 52(5):813-9. PubMed ID: 14563893
[TBL] [Abstract][Full Text] [Related]
17. Outcomes associated with amphotericin B lipid complex (ABLC) prophylaxis in high-risk liver transplant patients.
Saliba F; Delvart V; Ichaï P; Kassis N; Botterel F; Mihaila L; Azoulay D; Adam R; Castaing D; Bretagne S; Samuel D
Med Mycol; 2013 Feb; 51(2):155-63. PubMed ID: 22800082
[TBL] [Abstract][Full Text] [Related]
18. Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial.
Rijnders BJ; Cornelissen JJ; Slobbe L; Becker MJ; Doorduijn JK; Hop WC; Ruijgrok EJ; Löwenberg B; Vulto A; Lugtenburg PJ; de Marie S
Clin Infect Dis; 2008 May; 46(9):1401-8. PubMed ID: 18419443
[TBL] [Abstract][Full Text] [Related]
19. Ten years' experience with liposomal amphotericin B in transplant recipients at Huddinge University Hospital.
Ringdén O
J Antimicrob Chemother; 2002 Feb; 49 Suppl 1():51-5. PubMed ID: 11801582
[TBL] [Abstract][Full Text] [Related]
20. Liposomal amphotericin B, AmBisome.
Hay RJ
J Infect; 1994 May; 28 Suppl 1():35-43. PubMed ID: 8077689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
